tiprankstipranks
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
US Market
HRMY
Harmony Biosciences Holdings
RESEARCH TOOLSreports
Want to see HRMY full AI Analyst Report?

Harmony Biosciences Holdings (HRMY) Stock Forecast & Price Target

435 Followers
See the Price Targets and Ratings of:

HRMY Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Harmony
Biosciences Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HRMY Stock 12 Month Forecast

Average Price Target

$43.75
▲(45.88% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Harmony Biosciences Holdings in the last 3 months. The average price target is $43.75 with a high forecast of $72.00 and a low forecast of $25.00. The average price target represents a 45.88% change from the last price of $29.99.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","73":"$73","36.25":"$36.3","48.5":"$48.5","60.75":"$60.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,36.25,48.5,60.75,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,31.34769230769231,34.73538461538462,38.12307692307692,41.51076923076923,44.89846153846154,48.286153846153844,51.673846153846156,55.06153846153846,58.449230769230766,61.83692307692308,65.22461538461539,68.6123076923077,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,29.174615384615386,30.38923076923077,31.603846153846156,32.81846153846154,34.033076923076926,35.24769230769231,36.46230769230769,37.676923076923075,38.89153846153846,40.106153846153845,41.32076923076923,42.535384615384615,{"y":43.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,27.96,27.732307692307693,27.504615384615384,27.276923076923076,27.04923076923077,26.821538461538463,26.593846153846155,26.366153846153846,26.138461538461538,25.91076923076923,25.683076923076925,25.455384615384617,25.22769230769231,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":32.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.56,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.92,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.57,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$72.00Average Price Target$43.75Lowest Price Target$25.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on HRMY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$55
Buy
83.39%
Upside
Reiterated
04/22/26
H.C. Wainwright views weakness in Harmony shares as 'excessive IP overhang'H.C. Wainwright views weakness in Harmony shares as 'excessive IP overhang'
Oppenheimer Analyst forecast on HRMY
Jay Olson
Oppenheimer
Oppenheimer
$62→$72
Buy
140.08%
Upside
Reiterated
04/22/26
Harmony Biosciences price target raised to $72 from $62 at OppenheimerHarmony Biosciences price target raised to $72 from $62 at Oppenheimer
Piper Sandler Analyst forecast on HRMY
David Amsellem
Piper Sandler
Piper Sandler
$46
Buy
53.38%
Upside
Reiterated
04/22/26
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO)
Mizuho Securities Analyst forecast on HRMY
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$50
Buy
66.72%
Upside
Reiterated
04/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS), Greenwich LifeSciences (NASDAQ: GLSI) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Needham Analyst forecast on HRMY
Ami Fadia
Needham
Needham
$44
Buy
46.72%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: ICU Medical (NASDAQ: ICUI) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Deutsche Bank Analyst forecast on HRMY
David Hoang
Deutsche Bank
Deutsche Bank
$31→$30
Hold
0.03%
Upside
Reiterated
02/25/26
Harmony Biosciences downgraded to Hold from Buy at Deutsche BankHarmony Biosciences downgraded to Hold from Buy at Deutsche Bank
Truist Financial Analyst forecast on HRMY
Danielle Brill
Truist Financial
Truist Financial
$25
Hold
-16.64%
Downside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: ProQR (NASDAQ: PRQR), Immunic (NASDAQ: IMUX) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Bank of America Securities Analyst forecast on HRMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$32→$28
Sell
-6.64%
Downside
Reiterated
02/24/26
Harmony Biosciences price target lowered to $28 from $32 at BofAHarmony Biosciences price target lowered to $28 from $32 at BofA
UBS Analyst forecast on HRMY
Ashwani Verma
UBS
UBS
$50→$43
Buy
43.38%
Upside
Reiterated
10/14/25
UBS Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)
Cantor Fitzgerald Analyst forecast on HRMY
Charles Duncan
Cantor Fitzgerald
Cantor Fitzgerald
$54→$50
Buy
66.72%
Upside
Reiterated
09/24/25
Harmony Biosciences Holdings (HRMY) Receives a Buy from Cantor Fitzgerald
Goldman Sachs Analyst forecast on HRMY
Corinne Johnson
Goldman Sachs
Goldman Sachs
$33
Hold
10.04%
Upside
Initiated
07/10/25
Harmony Biosciences Holdings (HRMY) Gets a Hold from Goldman Sachs
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on HRMY
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$55
Buy
83.39%
Upside
Reiterated
04/22/26
H.C. Wainwright views weakness in Harmony shares as 'excessive IP overhang'H.C. Wainwright views weakness in Harmony shares as 'excessive IP overhang'
Oppenheimer Analyst forecast on HRMY
Jay Olson
Oppenheimer
Oppenheimer
$62→$72
Buy
140.08%
Upside
Reiterated
04/22/26
Harmony Biosciences price target raised to $72 from $62 at OppenheimerHarmony Biosciences price target raised to $72 from $62 at Oppenheimer
Piper Sandler Analyst forecast on HRMY
David Amsellem
Piper Sandler
Piper Sandler
$46
Buy
53.38%
Upside
Reiterated
04/22/26
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Crescent Biopharma (CBIO)
Mizuho Securities Analyst forecast on HRMY
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
$50
Buy
66.72%
Upside
Reiterated
04/21/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS), Greenwich LifeSciences (NASDAQ: GLSI) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Needham Analyst forecast on HRMY
Ami Fadia
Needham
Needham
$44
Buy
46.72%
Upside
Reiterated
04/14/26
Analysts Offer Insights on Healthcare Companies: ICU Medical (NASDAQ: ICUI) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Deutsche Bank Analyst forecast on HRMY
David Hoang
Deutsche Bank
Deutsche Bank
$31→$30
Hold
0.03%
Upside
Reiterated
02/25/26
Harmony Biosciences downgraded to Hold from Buy at Deutsche BankHarmony Biosciences downgraded to Hold from Buy at Deutsche Bank
Truist Financial Analyst forecast on HRMY
Danielle Brill
Truist Financial
Truist Financial
$25
Hold
-16.64%
Downside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: ProQR (NASDAQ: PRQR), Immunic (NASDAQ: IMUX) and Harmony Biosciences Holdings (NASDAQ: HRMY)
Bank of America Securities Analyst forecast on HRMY
Jason Gerberry
Bank of America Securities
Bank of America Securities
$32→$28
Sell
-6.64%
Downside
Reiterated
02/24/26
Harmony Biosciences price target lowered to $28 from $32 at BofAHarmony Biosciences price target lowered to $28 from $32 at BofA
UBS Analyst forecast on HRMY
Ashwani Verma
UBS
UBS
$50→$43
Buy
43.38%
Upside
Reiterated
10/14/25
UBS Reaffirms Their Buy Rating on Harmony Biosciences Holdings (HRMY)
Cantor Fitzgerald Analyst forecast on HRMY
Charles Duncan
Cantor Fitzgerald
Cantor Fitzgerald
$54→$50
Buy
66.72%
Upside
Reiterated
09/24/25
Harmony Biosciences Holdings (HRMY) Receives a Buy from Cantor Fitzgerald
Goldman Sachs Analyst forecast on HRMY
Corinne Johnson
Goldman Sachs
Goldman Sachs
$33
Hold
10.04%
Upside
Initiated
07/10/25
Harmony Biosciences Holdings (HRMY) Gets a Hold from Goldman Sachs
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Harmony Biosciences Holdings

3 Months
xxx
Success Rate
8/14 ratings generated profit
57%
Average Return
+0.59%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +0.59% per trade.
1 Year
David AmsellemPiper Sandler
Success Rate
8/15 ratings generated profit
53%
Average Return
-0.08%
Copying David Amsellem's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of -0.08% per trade.
2 Years
xxx
Success Rate
6/14 ratings generated profit
43%
Average Return
-0.74%
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -0.74% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HRMY Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
5
4
6
5
8
Buy
12
12
8
5
2
Hold
0
0
6
6
6
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
18
17
21
17
17
In the current month, HRMY has received 10 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. HRMY average Analyst price target in the past 3 months is 43.75.
Each month's total comprises the sum of three months' worth of ratings.

HRMY Financial Forecast

HRMY Earnings Forecast

Next quarter’s earnings estimate for HRMY is $0.71 with a range of $0.52 to $0.90. The previous quarter’s EPS was $0.38. HRMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.
Next quarter’s earnings estimate for HRMY is $0.71 with a range of $0.52 to $0.90. The previous quarter’s EPS was $0.38. HRMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.

HRMY Sales Forecast

Next quarter’s sales forecast for HRMY is $223.84M with a range of $207.21M to $234.05M. The previous quarter’s sales results were $243.78M. HRMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.
Next quarter’s sales forecast for HRMY is $223.84M with a range of $207.21M to $234.05M. The previous quarter’s sales results were $243.78M. HRMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HRMY has Performed in-line its overall industry.

HRMY Stock Forecast FAQ

What is HRMY’s average 12-month price target, according to analysts?
Based on analyst ratings, Harmony Biosciences Holdings’s 12-month average price target is 43.75.
    What is HRMY’s upside potential, based on the analysts’ average price target?
    Harmony Biosciences Holdings has 45.88% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HRMY a Buy, Sell or Hold?
          Harmony Biosciences Holdings has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Harmony Biosciences Holdings’s price target?
            The average price target for Harmony Biosciences Holdings is 43.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $72.00 ,the lowest forecast is $25.00. The average price target represents 45.88% Increase from the current price of $29.99.
              What do analysts say about Harmony Biosciences Holdings?
              Harmony Biosciences Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of HRMY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.